» Articles » PMID: 38464389

A Case of Immunotherapy-induced Thyroiditis

Overview
Specialty Oncology
Date 2024 Mar 11
PMID 38464389
Authors
Affiliations
Soon will be listed here.
Abstract

Immunotherapy treatments for cancer are known to cause adverse thyroid events which present a diagnostic challenge to clinicians and radiologists. This case report highlights the importance of a high clinical index of suspicion and careful assessment of the thyroid on serial imaging studies to make the diagnosis. The case involves a 65-year-old male with malignant melanoma who was started on immunotherapy as part of a clinical trial. He developed thyroid dysfunction followed by an attack of acute neck pain. Ultrasound of his thyroid was performed which showed significant atrophy. A review of previous imaging was undertaken which confirmed the patient had suffered from thyroiditis and subsequent atrophy. Following this, the diagnosis of immunotherapy-induced thyroid dysfunction was made. Thyroxine supplementation and steroid dose were then adjusted causing his thyroid function and symptoms to improve. Immunotherapy agents for cancers are becoming more and more common. As the case report shows, physicians and radiologists will need to be vigilant to diagnose and treat any adverse events.

References
1.
Middlebrooks E, Westbrook B, Conry R . Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?. Radiol Case Rep. 2018; 13(1):89-91. PMC: 5850905. DOI: 10.1016/j.radcr.2017.09.008. View

2.
Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R . Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy. Adv Sci (Weinh). 2021; 9(5):e2103444. PMC: 8844476. DOI: 10.1002/advs.202103444. View

3.
Ralli M, Botticelli A, Visconti I, Angeletti D, Fiore M, Marchetti P . Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020; 2020:9235638. PMC: 7338969. DOI: 10.1155/2020/9235638. View

4.
Simeone E, Grimaldi A, Festino L, Trojaniello C, Vitale M, Vanella V . Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Manag. 2019; 6(4):MMT30. PMC: 6920742. DOI: 10.2217/mmt-2019-0005. View

5.
Delivanis D, Gustafson M, Bornschlegl S, Merten M, Kottschade L, Withers S . Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017; 102(8):2770-2780. PMC: 5546861. DOI: 10.1210/jc.2017-00448. View